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osting by EAbstract Background and aim: Soluble CD40 ligand (sCD40L, also known as CD154) is a marker
for platelet activation which could increase coagulation and inﬂammation. In this case-control
study, we aimed to assess the levels of plasma sCD40L, IL-6, and some hemostatic parameters in
patients with metabolic syndrome (MetS) whether or not associated with overt ischemic heart dis-
ease (IHD).
Subjects and methods: We measured plasma sCD40L (an index of platelet activation), interleukin
(IL)-6 (a proinﬂammatory cytokine), and some hemostatic parameters (tissue factor [TF], throm-
bin–antithrombin [TAT] and D-dimer) in 47 patients with metabolic syndrome (21 with and 26
without overt IHD) versus 25 comparable healthy control subjects.
Results: Signiﬁcantly higher levels of sCD40L, IL-6, and thrombotic markers (TF, D-dimer and
TAT) were found in patients with metabolic syndrome compared to healthy controls. The levels
of IL-6 and sCD40 were highest in patients with overt IHD. Strong positive correlations existedpartment of Cardiology, Spe-
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132 N. El-Shahhat et al.between sCD40L and IL-6 (r= 0.67, p= 0.003), TF (r= 0.59, p= 0.008), and platelets count
(r= 0.64, p= 0.005).
Conclusion: Higher levels of sCD40L, IL-6, and thrombotic markers exist in MetS patients, partic-
ularly those with IHD. The strong positive correlations between sCD40L and IL-6, TF, and plate-
lets count support a link between the CD40–CD40L system and the underlying inﬂammatory and
hypercoagulable state in MetS patients.
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CD40L (L stands for ligand), a trimetric transmembrane pro-
tein of the tumor necrosis family also known as CD154, was
originally identiﬁed on the cells of the immune system.1 It
binds to CD40 on cells such as endothelial cells, monocytes,
and dendritic cells.2 CD40L is also stored in platelets and
translocated to the platelet surface upon stimulation within
seconds after activation in vitro and in vivo.3 Surface-ex-
pressed CD40L is then cleaved and/or released from the plate-
let over a period of minutes to hours, subsequently generating
a soluble fragment, soluble CD40L (sCD40L).4 sCD40L can
promote inﬂammatory or thrombotic response by causing fur-
ther platelet activation.5 This can occur through binding to
platelet CD40 or to the integrin.6,7 More than 95% of the cir-
culating CD40L exists in platelets, and the role of platelets was
already explained as inﬂammatory cells.8,9
First, platelets release a wide range of inﬂammatory medi-
ators from the intracellular stores such as several chemokines.
Second, platelets not only express and release inﬂammatory
mediators but upon activation may also induce the expression
of such substances in other cells (e.g., monocytes/macrophages
and granulocytes). Finally, platelets may themselves respond
to inﬂammatory mediators. In fact, platelets recently have
been found to express several chemokine receptors that upon
stimulation enhance platelet activation. Hence, platelets may
not only promote thrombus formation during activation but
also seem to release and express inﬂammatory mediators.
Brandt et al.10 concluded from their study that the generation
of inﬂammatory signals by platelets may occur following acute
mechanical damage of the endothelium or infection of the vas-
cular system. Platelet-associated CD40L – on exposure to
CD40-expressing vascular cells (including endothelial cells) –
induces the expression of adhesion molecules, the release of
inﬂammatory cytokines, e.g., interleukin (IL)-6, and the proco-
agulant tissue factor (TF).11 Surface-expressed CD40L is sub-
sequently cleaved to generate the soluble fragment sCD40L.
This soluble fragment retains much of its biological activities
by virtue of binding to glycoprotein IIb/IIIa and the induction
of signaling reactions when bound to the receptors.12 Like sol-
uble P-selectin (sP-sel), circulating sCD40L is believed to de-
rive predominantly from the activated platelets and hence
may reﬂect platelet activation.13 Therefore, these data suggest
a link between platelet activation, thrombogenesis, and the
inﬂammatory state in metabolic syndrome (MetS).14
MetS has been identiﬁed as a signiﬁcant and multifaceted
risk factor for cardiovascular disease (CVD) by the United
States National Cholesterol Education Program Adult Treat-
ment Panel (ATP)-III report.15 MetS includes the clusteringof abdominal obesity, insulin resistance, microalbuminuria,
dyslipidemia, and elevated blood pressure and is associated
with other abnormalities including the prothrombotic and pro-
inﬂammatory states, non-alcoholic fatty liver disease, and
reproductive disorders.16 MetS doubles coronary heart disease
mortality, after adjustment for age, sex, cholesterol level, phys-
ical activity, and smoking.17 In Ischemic Heart Disease Risk
Factor Study, men with MetS had a threefold increase in cor-
onary death, after adjusting for age, LDL cholesterol, smok-
ing, and family history.18 MetS is associated with an
approximate doubling of the cardiovascular disease risk and
a ﬁvefold increased risk for incident type 2 diabetes mellitus.
Although it is unclear whether there is a unifying pathophysi-
ological mechanism resulting in the MetS, abdominal adipos-
ity and insulin resistance appear to be central to this
syndrome. Life style modiﬁcation and weight loss should
therefore be the cornerstone for treating or preventing MetS
and its components.19 In addition, there is a general consensus
that the other cardiac risk factors should be aggressively man-
aged in individuals with MetS. Finally, MetS is an evolving
concept that continues to be data-driven and evidence-based
with revisions forthcoming.20 The aim of the present study
was therefore designed to assess the behavior of plasma
sCD40L levels in patients with MetS. Furthermore we sought
to determine if a relationship could exist between sCD40L and
hemostatic abnormalities in MetS patients.
2. Subjects and methods
Blood samples were obtained from 25 healthy volunteers (con-
trols) not taking any antiplatelet medications within 7 days be-
fore sampling; and 47 MetS patients who were admitted to our
hospital (26 without and 21 with overt ischemic heart disease
[IHD]). Informed consent was obtained from all subjects.
None of the subjects had any clinical evidence of the
peripheral vascular disease or inﬂammatory conditions. Poten-
tial patients with infection, tumors, diabetes, hypertension, li-
ver or kidney disease were also excluded. All patients with
overt IHD were those with unstable angina who had experi-
enced ischemic chest pain at rest within the preceding 48 h
but had no evidence of myocardial necrosis by enzymatic cri-
teria.Both patients and controls were subjected to:
1. Thorough history and clinical examination
2. Routine laboratory investigations: Complete blood count,
fasting lipogram (total cholesterol, HDL-C, LDL-C, TG),
fasting serum glucose level, Troponin T, and HbA1c (mea-
sured by liquid chromatography [BioRad]).21
3. Speciﬁc investigations included
Table 1 Comparison of means of cytokine levels and hemostatic variables in the studied groups.
Controls (n= 25) MS with IHD (n= 26) MS without IHD (n= 21) p-value
sCD40L (pg/ml) 76.7 ± 38.1 501.8 ± 181.7 807.2 ± 264.5 0.001*
IL-6 (pg/ml) 246.2 ± 131.7 683.3 ± 134.6 690.8 ± 138.7 0.001*
Tissue factor (pg/ml) 392.7 ± 111.6 645.3 ± 242.7 1405.6 ± 264.5 0.001*
TAT (ng/ml) 11.9 ± 4.8 22.8 ± 7.3 26.4 ± 9.6 0.055
D-Dimer (ng/ml) 188.2 ± 62.7 316.7 ± 89.6 694.0 ± 271.9 0.001*
* Signiﬁcant at p< 0.01.
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Concentrations of sCD40L were determined using a
commercially available enzyme immunoassay (Bender
Med Systems GmBH, Austria) with a detection limit
of 95 pg/ml (0.095 ng/mL). The following antibodies
were used: mouse-anti-human-CD40, mouse-anti-
human- CD40L, and mouse IgG-PE-conjugated.22
(b) ELISA (Enzyme-Linked Immuno Sorbent Assay) for
IL-6: ELISA kits (AviBion Human IL-6, ELISA, V-
antaa, Finland) containing the micro titration plate
with adsorbed conjugate of the mouse monoclonal
antibody against determined antigens and nonspeciﬁc
horseradish peroxidase were used. Every plate con-
tained a doublet of 7 standards for the construction
of the calibration curve and blank. The pH of the
washing phosphate-buffered saline solution with 1%
tween 20 was adjusted to 7.4. A tetramethyl benzidine
(TMB) solution served as the substrate for the redox
reaction. Activity of the enzyme was stopped by 1 M
phosphoric acid and absorbance was measured at 4-
50 nm ﬁlter. The detection limit was <500 pg/ml.23
(c) Hemostatic parameters: Automated analysis of thr-
ombin–antithrombin (TAT) complexes levels took
place in the coagulation analyzer (Dad Behring, Mar-
burg GmbH agnostica Stago, Inc.) which implements
an antibody that reacts with the modiﬁed antithrom-
bin (AT)-III found in the AT-III/protease complexes.
The major component of the AT-III protease com-
plexes is the combination of AT-III with thrombin.
The reference range for this assay is <20 ng/ml.
(d) Dimer and tissue factor (TF) MeasurementPlasma
D-dimer levels were measured by the Mini-VIDAS
ELISA method (bioMerieux-France).2.1 Statistical analyses
Data analyses were performed with SPSS for Windows version
13 (SPSS Inc., Chicago, IL). Results are expressed as the
mean ± standard deviation of the mean for continuous data.
Comparison of the means of different continuous variables in
the three studied groups was performed with one-way ANOVA
test. A two-sided signiﬁcance level of 0.05 was used for all
analyses.3. Results
As shown in Table 1, the mean values of sCD40L, IL-6, TF,
TAT, and D-dimer showed a signiﬁcant trend to increases as
we move from ‘‘control’’ to ‘‘MS with IHD’’ to ‘‘MS withoutIHD’’. Besides, the ﬁve variables showed a signiﬁcant differ-
ence regarding their levels in controls when compared to the
MS patients. In other words, the mean value in MS patients
(whether or not having IHD) was signiﬁcantly higher com-
pared to controls. Besides, the mean value of these variables
within the MS patients was signiﬁcantly higher in the IHD pa-
tients when compared to those without IHD (apart from IL-6
and TAT, where the difference was not statistically signiﬁcant).
Regarding the correlations, we found a strong positive cor-
relation between sCD40L and IL-6 (r= 0.67, p= 0.003), TF
(r= 0.59, p= 0.008), and platelets count (r= 0.64,
p= 0.005).
4. Discussion
sCD40L is an important link between inﬂammation, athero-
sclerosis and thrombosis. Consistent with the previous reports,
these results showed higher levels of sCD40L in patients with
MetS compared with controls. This is explained by Garlichs
et al.24 who reported that platelets express the transmembrane
signaling protein CD40L within seconds of activation. After
activation with thrombin, adenosine diphosphate (ADP), or
collagen; a soluble form of CD40L is also released. Entmann
et al.25 demonstrated that CD40L binds to platelet CD40 lead-
ing to further cleavage of the membrane-bound CD40L and
the release of soluble CD40L. The present study shows that
MetS patients with unstable angina had signiﬁcantly higher
levels of sCD40L and IL-6 compared with both controls and
patients without IHD. Grewal et al.26 believed that the in-
creased serum levels of sCD40L in patients with unstable angi-
na are not only a marker of immune activation, but may also
be involved in the pathogenic processes in these patients.
sCD40L in the circulation may pass through damaged athero-
sclerotic endothelium and come into direct contact with the
cells inside the lesion. However, sCD40L may activate circulat-
ing leukocytes to enhance the release of proinﬂammatory cyto-
kines,27 increase the expression of adhesion molecules, and
enhance the release of CC-chemokines (i.e., monocyte chemo-
attractant protein [MCP]-1) in mononuclear cells. Such an
activation of the circulating leukocytes may be facilitated at
the endothelium outside an atherosclerotic plaque with up-reg-
ulation of the adhesion molecules. These inﬂammatory re-
sponses mediated by sCD40L may further promote the
inﬁltration of the activated leukocytes into the atherosclerotic
lesion. This in turn may directly activate macrophages and T-
cells inside the vascular wall.28 Higher CD40L levels in pa-
tients with unstable angina may reﬂect important pathogenic
aspects in these patients. The rupture of an atherosclerotic pla-
que, which again triggers thrombosis, is an important patho-
genic event in the development of acute coronary
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patients with MetS with and without IHD, being highest in pa-
tients with overt IHD. This is explained by Volpato et al.30
who reported that CD40L stimulation increases the expression
of adhesion molecules, chemokines, and inﬂammatory cyto-
kines especially IL-6, IL-1 and IL-8 from the vascular endothe-
lial cells leading to the recruitment and activation of leukocytes
within the atherosclerotic plaque. Kazes et al.31 reported that
CD40 ligation on monocytes and dendritic cells results in:
(1) an enhanced survival of these cells; (2) the secretion of cyto-
kines (such as IL-6, IL-1, IL-8, IL-10, IL-12, TNF-a) and en-
zymes such as matrix metalloproteinase (MMP); (3) enhanced
monocyte tumoricidal activity. Increased level of IL-6 in pa-
tients with IHD was explained by Loppnow et al.32 who re-
ported that MCP-1 regulates monocyte and macrophage
migration and inﬁltration to the sites of active inﬂammation.
MCP-1 further induces proinﬂammatory cytokines, chemo-
kines, and MMPs. Then, the proinﬂammatory IL-6 promotes
vascular smooth muscle cell proliferation at the inﬂamed
plaques.
This study also demonstrated an increase in the hemostatic
parameters in patients with MetS especially if associated with
overt IHD, in line with a previous report.33 Ridker et al.34
hypothesized that CD40L over-expression may be a stimulus
for clotting activation. This hypothesis is based on previous
studies35–38 demonstrating that in monocytes, endothelial cells,
and smooth muscle cells CD40L over-expression facilitates
atherosclerotic plaque rupture; exposing collagen and von
Willebrand factor on the damaged endothelium to create an
extensive surface for platelet adhesion. Adherent platelets sub-
sequently aggregate, following the release of a variety of plate-
let intracellular signaling molecules including thromboxane
A2, ADP, serotonin, and epinephrine in addition to the sys-
temically circulating thrombin. Additional platelets are re-
cruited to the site of injury and adhesion where
conformational changes in platelet cytoskeletal proteins result
in up-regulation and expression of Gp IIb/IIIa on the platelet
receptors surfaces.36 The binding of Gp IIb/IIIa receptors to
ﬁbrinogen causes extensive cross-linking, which facilitates
thrombus formation.37
In patients without overt IHD, sCD40L showed non-signif-
icant correlations with any of the hemostatic factors or IL-6;
while in patients with IHD, we found strong positive correla-
tions between sCD40L and IL-6 (r= 0.67, p= 0.003), TF
(r= 0.59, p= 0.008), and platelets count (r= 0.64,
p= 0.005); hence supporting a link between the CD40–
CD40L system and the underlying inﬂammatory and hyperco-
agulable state in these patients. Also, the positive correlation
between sCD40L and platelet count raises a question about
the origin of this mediator. Major studies on the cellular distri-
bution of CD40L indicate that >95% of the circulating
sCD40L exists in platelets. In fact, activated platelets have
been found to stimulate the adhesion molecule and MCP-1
production in endothelial cells through the enhanced sCD40L
secretion and direct platelet–endothelium contact mediated by
CD40L expression on the platelet surface.38 In addition, the in-
crease in sCD40L in patients with overt IHD expressing high
levels of TF and IL-6 has been associated with more adverse
cardiovascular outcomes and the development of coronary
events compared to subjects without clinically established
IHD.5. Conclusion
High levels of sCD40L, IL-6, and thrombotic markers exist in
patients with MetS syndrome compared to healthy individuals;
particularly in MetS patients with IHD .Thus, the elevated
plasma sCD40L levels in patients with MetS (especially those
with overt IHD) can be reduced by the intensive application
of a package of multifactorial cardiovascular risk intervention
strategy.
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